Marc Van Dijk

419 total citations
23 papers, 256 citations indexed

About

Marc Van Dijk is a scholar working on Immunology, Oncology and Radiology, Nuclear Medicine and Imaging. According to data from OpenAlex, Marc Van Dijk has authored 23 papers receiving a total of 256 indexed citations (citations by other indexed papers that have themselves been cited), including 16 papers in Immunology, 15 papers in Oncology and 7 papers in Radiology, Nuclear Medicine and Imaging. Recurrent topics in Marc Van Dijk's work include CAR-T cell therapy research (12 papers), Immune Cell Function and Interaction (9 papers) and Immunotherapy and Immune Responses (8 papers). Marc Van Dijk is often cited by papers focused on CAR-T cell therapy research (12 papers), Immune Cell Function and Interaction (9 papers) and Immunotherapy and Immune Responses (8 papers). Marc Van Dijk collaborates with scholars based in United States, Germany and Netherlands. Marc Van Dijk's co-authors include Volker Seibert, Petra Herzig, Frank Stenner, P.G.M. Bloemen, Henk‐Jan Schuurman, Christoph Renner, Pascal Lecomte, A C Bloem, Alfred Zippelius and Dennis Underwood and has published in prestigious journals such as The Journal of Experimental Medicine, Journal of Clinical Oncology and SHILAP Revista de lepidopterología.

In The Last Decade

Marc Van Dijk

21 papers receiving 249 citations

Peers

Marc Van Dijk

IMMUN

ONCOL

RNMI

PMH

Svetlana Paskaš Serbia

Sofia Cotton Portugal

Tomasz Kubiatowski Poland

Rintu Thomas United States

Joachim Diessner Germany

Heidi Salminen Finland

Manmohan R. Leleti United States

E. McDermott Ireland

Sagrario Montero Spain

Katrien Geboers Belgium

Svetlana Paskaš Serbia

Marc Van Dijk

58 ×0.5

IMMUN

88 ×1.1

66 ×0.8

ONCOL

72 ×2.3

RNMI

9 ×0.4

PMH

Citations per year, relative to Marc Van Dijk Marc Van Dijk (= 1×) peers Svetlana Paskaš

Countries citing papers authored by Marc Van Dijk

Since Specialization

Citations

This map shows the geographic impact of Marc Van Dijk's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Marc Van Dijk with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Marc Van Dijk more than expected).

Fields of papers citing papers by Marc Van Dijk

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Marc Van Dijk. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Marc Van Dijk. The network helps show where Marc Van Dijk may publish in the future.

Co-authorship network of co-authors of Marc Van Dijk

This figure shows the co-authorship network connecting the top 25 collaborators of Marc Van Dijk. A scholar is included among the top collaborators of Marc Van Dijk based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Marc Van Dijk. Marc Van Dijk is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Popis, Martyna, Shanmugarajan Krishnan, Deborah Wright, et al.. (2024). 753 AgenT-797 cell therapy can be combined with next-generation immune checkpoint inhibitors (ICI) and/or bi-specific engagers to improve anti-cancer response. Regular and Young Investigator Award Abstracts. A857–A857. 1 indexed citations

Moon, Jamie, John Hamm, Benedito A. Carneiro, et al.. (2023). 735 Peripheral and tissue persistence of agenT-797, an allogeneic iNKT cell-based cell therapy for the treatment of cancer. SHILAP Revista de lepidopterología. A828–A828. 3 indexed citations

Michelet, Xavier, Martyna Popis, Shannon K. Boi, et al.. (2022). 358 Development of an allogenic FAP CAR iNKT product to target tumor stroma and modulate the tumor microenvironment. Regular and Young Investigator Award Abstracts. A377–A377. 1 indexed citations

Chamberland, John P., Qin Yu, Reed Masakayan, et al.. (2022). 372 agenT-797, a native allogeneic “off-the-shelf” invariant natural killer T (iNKT) cell therapy product improves effector functions within the tumor microenvironment. Regular and Young Investigator Award Abstracts. A391–A391.

Masakayan, Reed, Martyna Popis, Paul Ibbett, et al.. (2022). 322 MiNK-413: a next generation armored allogenic BCMA CAR iNKT product. Regular and Young Investigator Award Abstracts. A338–A338. 1 indexed citations

Purbhoo, Marco A., et al.. (2021). 400 Persistence and tissue distribution of agent-797 – a native allogeneic iNKT cell-therapy drug product. Regular and Young Investigator Award Abstracts. A432–A432. 1 indexed citations

Michelet, Xavier, Jan Bergmann, Simon Yue, et al.. (2020). 164 AgenT-797, a novel allogenic and ‘off-the shelf’ iNKT cell therapy promotes effective tumor killing. SHILAP Revista de lepidopterología. A98.1–A98. 1 indexed citations

Galand, C, James Strauss, Richard D. Carvajal, et al.. (2020). 377 AGEN2373 is a CD137 agonist antibody designed to leverage optimal CD137 and FcγR co-targeting to promote antitumor immunologic effects. SHILAP Revista de lepidopterología. A229.2–A230. 6 indexed citations

Stenner, Frank, Volker Seibert, Petra Herzig, et al.. (2019). Humanized Monoclonal Antibody Blocking Carbonic Anhydrase 12 Enzymatic Activity Leads to Reduced Tumor Growth In Vitro. Anticancer Research. 39(8). 4117–4128. 10 indexed citations

10.

Chaipan, Chawaree, Sandra Wimberger, Jun Seop Jeong, et al.. (2019). TCR Fingerprinting and Off-Target Peptide Identification. Frontiers in Immunology. 10. 2501–2501. 31 indexed citations

11.

Galand, C, Yanping Xiao, Cornelia Mundt, et al.. (2019). AGEN2373 is a conditionally-active agonist antibody targeting the costimulatory receptor CD137 for the treatment of human malignancies.. Journal of Clinical Oncology. 37(15_suppl). e14005–e14005.

12.

Savitsky, David A., Rebecca Ward, Cornelia Mundt, et al.. (2018). Abstract 3819: INCAGN02385 is an antagonist antibody targeting the co-inhibitory receptor LAG-3 for the treatment of human malignancies. Cancer Research. 78(13_Supplement). 3819–3819. 22 indexed citations

13.

González-Castro, Ana María, Mariana Manrique, Ekaterina Breous, et al.. (2016). Abstract 3204: INCAGN01949: an anti-OX40 agonist antibody with the potential to enhance tumor-specific T-cell responsiveness, while selectively depleting intratumoral regulatory T cells. Cancer Research. 76(14_Supplement). 3204–3204. 4 indexed citations

14.

Giron‐Michel, Julien, Manuela Fogli, Alessia Gaggero, et al.. (2003). Detection of a Functional Hybrid Receptor γc/GM-CSFRβ in Human Hematopoietic CD34+ Cells. The Journal of Experimental Medicine. 197(6). 763–775. 18 indexed citations

15.

Giron‐Michel, Julien, Anne Caignard, Manuela Fogli, et al.. (2003). Differential STAT3, STAT5, and NF-κB activation in human hematopoietic progenitors by endogenous interleukin-15: implications in the expression of functional molecules. Blood. 102(1). 109–117. 43 indexed citations

16.

Lecomte, Pascal, et al.. (2000). A 1-Year Cost-Effectiveness Model for the Treatment of Chronic Schizophrenia with Acute Exacerbations in Belgium. Value in Health. 3(1). 1–11. 25 indexed citations

17.

Binder, Marc D., Marc Van Dijk, Pascal Lecomte, & G. Nuyts. (2000). A one year cost-effectiveness model for the treatment of chronic schizophrenia in Belgium. European Neuropsychopharmacology. 10. 316–316. 2 indexed citations

18.

Brakenhoff, Ruud H., et al.. (1997). A gain of novel tissue specificity in the human Ly-6 gene E48. The Journal of Immunology. 159(10). 4879–4886. 15 indexed citations

19.

Bloemen, P.G.M., et al.. (1992). Multiple ICAM‐1 (CD54) Epitopes are Involved in Homotypic B‐Cell Adhesion. Scandinavian Journal of Immunology. 35(5). 517–523. 23 indexed citations

20.

Dijk, Marc Van, et al.. (1982). Platinum compounds with anti-tumour activity. Mutation Research/Environmental Mutagenesis and Related Subjects. 97(3). 212–213. 2 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact